...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Thoracic Disease >Possible role of circulating tumor cells in early detection of lung cancer
【24h】

Possible role of circulating tumor cells in early detection of lung cancer

机译：循环肿瘤细胞在早期检测肺癌的可能作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The prognosis of lung cancer varies highly depending on the disease stage at diagnosis, from a 5-year survival rate close to 90% in stage I, to 10% or less in stage IV disease. The enhancement of early diagnosis of this malignancy is mandatory to improve prognosis, because lung cancer patients stay long asymptomatic or few symptomatic after disease onset. Nowadays, liquid biopsy has emerged as a minimally-invasive tool to address the urgent need for real time monitoring, stratification, and personalized treatment of malignancies, including lung cancer. Liquid biopsy refers to a class of biomarkers, including circulating tumor cells (CTCs), cell-free circulating tumor DNA (ctDNA) and tumor-derived extracellular vesicles (tdEV). Since CTCs represent a crucial step in disease progression and metastasis, we reviewed here the scientific literature about the use of CTCs in early diagnosis of lung cancer; different techniques, and different strategies (e.g., source of analysis sample or high-risk groups of patients) were discussed showing the potential of implementing liquid biopsy in the clinical routine of non-metastatic lung cancer.
机译：肺癌的预后依赖于诊断的疾病阶段的疾病阶段，从阶段I中的5年内存活率，阶段IV疾病中的10％或更低。这种恶性肿瘤早期诊断的增强是强制性的，以改善预后，因为肺癌患者在疾病发病后保持长的无症状或少数症状。如今，液体活组织检查已成为一种微创工具，以解决迫切需要实时监测，分层和对恶性肿瘤的个性化治疗，包括肺癌。液体活组织检查是指一类生物标志物，包括循环肿瘤细胞（CTC），无细胞循环肿瘤DNA（CTDNA）和肿瘤衍生的细胞外囊泡（TDEV）。由于CTC代表疾病进展和转移的关键步骤，我们在这里审查了CTC在肺癌早期诊断中使用CTC的科学文献;讨论了不同的技术和不同的策略（例如，分析样本或患者的高风险群体），显示在非转移性肺癌的临床常规中实施液体活检的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号